About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
OXOMEMAZINE HCL exhibits a multidimensional biochemical activity profile involving modulation of enzyme-catalyzed pathways, receptor-mediated intracellular signaling, ion-channel regulation, mitochondrial bioenergetics, oxidative-stress balancing, membrane dynamics, and transcription-factor orchestration. Its molecular configuration allows high-affinity interaction with catalytic residues, allosteric domains, regulatory scaffolds, and signaling intermediates, influencing phosphorylation cycles, secondmessenger flux (Ca²⁺, cAMP, IP, DAG), ROS equilibrium, ATP synthesis, and mitochondrial respiratory-chain regulation.
Depending on dose, exposure duration, and cell type, OXOMEMAZINE HCL can modify chromatin accessibility, metabolic flux routing, vesicular trafficking, cytoskeletal structure, and gene-expression clusters associated with survival, inflammation, apoptosis, autophagy, and metabolic adaptation.
Benefits and Advantages
Due to its consistent mechanistic behavior, this compound is utilized in advanced research, including:
- Receptorligand interaction studies and affinity modeling
- Highresolution enzyme kinetics and catalytic-pathway deconstruction
- Mitochondrial ATPflux assays and oxidativestress system modeling
- Multiomics profiling (transcriptomics, proteomics, metabolomics, phosphoproteomics)
- Cytoskeletal and membranedynamics exploration
- Apoptosis, ferroptosis, necroptosis, and autophagy pathway analysis
- Structureactivity relationship (SAR) investigations and compound optimization
- Pharmacodynamic modeling, mechanistic doseresponse scaling, and pathway benchmarking
Side Effects and Risks
Potential laboratory risks include:
- Oxidativestress imbalance and ROS accumulation
- Mitochondrial overload or respiratory-chain suppression
- Ionchannel dysregulation affecting Ca²⁺/Na⁺/K⁺ homeostasis
- Unintended receptor crossactivation or pathway inhibition
- Cytoskeletal destabilization and membrane-integrity disruption
- Dose-dependent cytotoxicity (apoptotic or autophagic induction)
- Transcriptional or epigenetic instability under prolonged exposure
- Activation of inflammatory signaling networks (NF-κB, JNK, p38 MAPK)
Use strictly in controlled laboratory environments with appropriate biosafety protocols.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C18H23ClN2O2S |
|---|---|
| Molecular Weight | 366.9 g/mol |
| CAS Number | 4784-40-1 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Oxomemazine hydrochloride; 4784-40-1; EINECS 225-330-4; UNII-6BOK44G9K6; 6BOK44G9K6 |
| IUPAC/Chemical Name | 3-(5,5-dioxophenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine;hydrochloride |
| InChl Key | NPMMOYKGIWLASW-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C18H22N2O2S.ClH/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20;/h4-11,14H,12-13H2,1-3H3;1H |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
